BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. $(BIIB)$ and UCB have announced the presentation of additional detailed results from their Phase 3 PHOENYCS GO study at the European Alliance of Associations for Rheumatology's annual meeting (EULAR 2025) in Barcelona, Spain. The study evaluates dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate, in patients with moderate-to-severe systemic lupus erythematosus $(SLE)$. The results demonstrated significant clinical improvements in disease activity, including fatigue and disease activity/remission, as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Dapirolizumab pegol is not yet approved for use in SLE by any regulatory authority, and a second Phase 3 trial is ongoing to confirm these findings.